Baystreet Staff -

Bioelectronic-Medicine Leader Endonovo Therapeutics, Inc. Begins 2016 on a Strong Note


LAS VEGAS, NV / ACCESSWIRE / January 19, 2016 / As the new year begins, Endonovo Therapeutics, Inc. (OTCQB: ENDV) surges to the forefront of the rapidly emerging bioelectronic medicine industry and is expected to provide substantial benefit to the treatment of inflammation in vital organs. Working to develop its non-invasive bioelectronics device, which it has coined "Immunotronics" to treat inflammatory conditions in vital organs, this biotechnology company is already one biotech industry stock investors will be closely watching throughout 2016.

Endonovo Therapeutics' technology was shown to produce significant reduction of inflammation in a Carrageenan Rat-Footpad Edema (CFE) protocol, which is the drug/pharmaceutical industry gold standard for the initial screening of drugs and their effects on acute inflammation. In that study, Endonovo's technology was confirmed as a potentially effective anti-inflammatory non-invasive bioelectronics device. Inflammation in vital organs fuels tissue damage which potentially leads to organ failure and subsequently death. Historically, the human body has relied upon the supporting functions of its body in a self-healing effort to resolve the inflammation on its own as no effective treatments for organ failure stemming from inflammation exists. The Company is currently gearing up its pre-clinical work to evaluate its technology's potential to treat and prevent organ failure and other inflammatory conditions in vital organs, such as the liver.

Endonovo appears to now be at the forefront of the emerging bioelectronic medicine industry, whose pipeline of products is currently filled with invasive implantable nerve-stimulators. Investors have already responded positively to Endonovo's technologies, sending the stock up from just 10 cents a share to just over 75 cents last month before the profit takers took the stock to around its current price. However, these advancements are expected to be highly influential in taking the stock back up to its recent highs.

With this technology and the numbers growing the way they are, Endonovo looks incredibly poised for major growth. This is similar to some of these other biotech stocks that have had similar kinds of growth patterns:Actinium Pharmaceuticals, Inc. (ATNM) is a biopharmaceutical company and is currently developing cancer treatments using its alpha particle immunotherapy (APIT) platform. The Company expects to see major improvements in its technology during 2016, specifically in regards to a Phase 3 clinical trial for its lead drug candidate, Iomab-B and a Phase 2 clinical trial for its cd33 targeting drug candidate, Actimab-A.

After facing a bumpy road at the end of 2015, Synta Pharmaceuticals Corp. (SNTA) is hoping to find stable ground during the coming months. The biopharmaceutical company, which is focusing on the key oncology drug candidate ganetespib (a heat shock protein 90 (Hsp90) inhibitor), announced in its Q3 results that it would be reducing its workforce by 60% to 33 full-time employees. The Company expects to see an annual savings of approximately $8 million, and the majority of related cash payments were paid out during the fourth quarter.

Chimerix, Inc. (CMRX) is taking another impressive route with its development of oral antivirals for the treatment of chronic diseases. The Company is currently in a Phase 3 clinical development process for its nucleotide analog lipid conjugate, brincidofovir (CMX001). Brincidofovir has produced responses against all five families of human DNA viruses, including ytomegalovirus (CMV), adenovirus (AdV), BK virus, and herpes simplex viruses.

Last but not least, Arena Pharmaceuticals, Inc. (ARNA) is another biopharmaceutical company to pay attention to during 2016. Its focus is on discovering, developing and commercializing drugs which target G protein-coupled receptors (GPCRs). The Company's introductory product, BELVIQ (lorcaserin HCl), is an FDA-approved prescription medication to aid in weight loss for adults who are overweight (Body Mass Index [BMI] ≥ 27kg/m2) or obese (BMI ≥ 30 kg/m 2). It is currently testing lorcaserin to identify possible benefits for smoking cessation.

Biotech stocks continue to help fuel gains for investors on multiple fronts. Position is everything when considering investing in microcap stocks. The way Endonovo Therapeutics, Inc. (ENDV) continue to handle themselves in their respected field and with their company structure, they look like a company investors should be watching very closely.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.commay from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns, Microcapspeculators.commay be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated a total of $8,000 cash by A non-affiliate third party of ENDV.


[email protected]

SOURCE: ACR Communication, LLC